VERU 📈 Veru - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92536C1036
VERU: Condoms, Cancer treatments, ARDS treatments
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Web URL: https://verupharma.com
Additional Sources for VERU Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
VERU Stock Overview
Market Cap in USD | 105m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Personal Care Products |
IPO / Inception | 1990-07-19 |
VERU Stock Ratings
Growth 5y | -64.5% |
Fundamental | -64.4% |
Dividend | 7.43% |
Rel. Strength Industry | -192 |
Analysts | 4.2/5 |
Fair Price Momentum | 0.52 USD |
Fair Price DCF | - |
VERU Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 24.8% |
VERU Growth Ratios
Growth Correlation 3m | -69.5% |
Growth Correlation 12m | 22.5% |
Growth Correlation 5y | -57.6% |
CAGR 5y | -26.27% |
CAGR/Mean DD 5y | -0.41 |
Sharpe Ratio 12m | 0.34 |
Alpha | -22.08 |
Beta | 0.42 |
Volatility | 101.99% |
Current Volume | 1503.1k |
Average Volume 20d | 1123k |
What is the price of VERU stocks?
As of December 22, 2024, the stock is trading at USD 0.65 with a total of 1,503,100 shares traded.
Over the past week, the price has changed by -15.55%, over one month by +0.29%, over three months by -21.49% and over the past year by -12.47%.
As of December 22, 2024, the stock is trading at USD 0.65 with a total of 1,503,100 shares traded.
Over the past week, the price has changed by -15.55%, over one month by +0.29%, over three months by -21.49% and over the past year by -12.47%.
Is Veru a good stock to buy?
No, based on ValueRay Fundamental Analyses, Veru (NASDAQ:VERU) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -64.41 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VERU as of December 2024 is 0.52. This means that VERU is currently overvalued and has a potential downside of -20%.
No, based on ValueRay Fundamental Analyses, Veru (NASDAQ:VERU) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -64.41 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VERU as of December 2024 is 0.52. This means that VERU is currently overvalued and has a potential downside of -20%.
Is VERU a buy, sell or hold?
Veru has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy VERU.
Veru has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy VERU.
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for VERU stock price target?
According to ValueRays Forecast Model, VERU Veru will be worth about 0.6 in December 2025. The stock is currently trading at 0.65. This means that the stock has a potential downside of -12.31%.
According to ValueRays Forecast Model, VERU Veru will be worth about 0.6 in December 2025. The stock is currently trading at 0.65. This means that the stock has a potential downside of -12.31%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.4 | 423.1% |
Analysts Target Price | 3.3 | 412.3% |
ValueRay Target Price | 0.6 | -12.3% |